Valneva Shares Updated Data From Now Shelved COVID-19 Vaccine Development Program
As previously announced, Valneva SE (NASDAQ:VALN) said it would not invest in further COVID-19 vaccine development, VLA2001, without a new…
Valneva Announced Additional Data From Remaining Studies And An Update On Regulatory Submissions For Its Inactivated Covid-19 Vaccine, VLA2001.
As previously announced, Valneva will not invest in further development of the vaccine, in the absence of a new partnership1. It is, however, completing remaining clinical studies and submissions as agreed with
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $25 Price Target
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $25 price target.
The FDA Has Completed A Filing Review Of Valneva’s Biologics License Application For Its Single-shot Chikungunya Vaccine Candidate, VLA1553
VLA1553 has been assigned a Prescription Drug User Fee Act (PDUFA) review goal date at the end of August 2023.
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $25 Price Target
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $25 price target.
Pfizer, Valneva Discontinue Certain Trial Sites For Phase 3 Study Of Lyme Disease Vaccine Candidate
Pfizer Inc (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announce that Pfizer, as the study sponsor, will discontinue a significant percentage of participants in the…
Pfizer And Valneva Announce That Pfizer, As The Study Sponsor, Has Decided To Discontinue A Significant Percentage Of Participants In The U.S. Who Had Been Enrolled In The Valor Phase 3 Study, Due To Violations Of Good Clinical Practice
The study is investigating the efficacy, safety, and immunogenicity of an investigational Lyme disease vaccine candidate, VLA15.
These study participants, representing approximately half of the total recruited
Valneva Reports Revenues Of €361.3M In 2022 Compared To €348.1M In 2021, An Increase Of 3.8%
Saint-Herblain (France), February 16, 2023 – Valneva SE (NASDAQ:VALN, PARIS:VLA) a specialty vaccine company, today reported its revenue and cash balance for the full year 2022 and provided
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $25 Price Target
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $25 price target.
Valneva Has Completed Enrollment And Vaccination For A Phase 3 VLA 1553-321 Trial In Adolescents Of Its Single-shot Chikungunya Vaccine Candidate, VLA 1553
The first results are expected in mid 2023.